Entrada Therapeutics, Inc.
TRDABiotechnology
$4.54+3.07%As of Oct 30vs prior close
- Market cap
- $176.6M
- P/E (TTM)
- –
- From 52W high
- −71.71%
- EPS (LTM)
- -$3.97
- Revenue (LTM)
- $4.7M
- Net margin
- -3537.73%
- Dividend yield
- 0.00%
Nomior Score
30
Steady ProfileBottom 15% of the scored universe
Growth52
Quality30
Value42
Momentum39
Resilience33
Growth
−55.61%revenue a year over 2 fiscal years
YE23 $129MLTM $4.7M
Connections
Revenue to profitQ2 YE26
The operating loss was 5007% of revenue, wider by 2605 pts on a year.
Who owns it
2funds